Drug | Form* | Daily dose µg | ||
---|---|---|---|---|
Low | Medium | High | ||
Source: Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA) 2019 http://www.ginasthma.org/ (the doses have been adjusted to the pharmaceutical preparations on the market in Finland) and Chung KF, Wenzel SE, Brozek JL ym. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2):343-73. [PubMed]. The doses have been estimated according to clinical comparability. They are only indicative and may vary from patient to patient. Most of the clinical benefit of the medication is usually seen at low doses already, and evidence on dose-response relationships is limited. The risk of adverse effects is usually increased with high doses in long-term use. * Nebulizer suspensions are not included in the table. ** HFA = hydrorofluoroalkane propellant *** Mometasone and ciclesonide can be administered once daily. | ||||
Beclomethasone | Powder | 200-500 | 500-1 000 | > 1 000 |
HFA** solution | 100-200 | 200-400 | > 400 | |
Budesonide | Powder | 200-400 | 400-800 | > 800 |
Budesonide | As part of a combination preparation | 160-320 | 320-640 | > 640 |
Fluticasone propionate | Powder HFA suspension | 100-250 | 250-500 | > 500 |
Fluticasone furoate (only in combined preparation) | Powder | - | 92 | HASH(0x2f82cc8) 184 |
Mometasone*** | Powder | 200 | 200-400 | > 400 |
Ciclesonide*** | HFA solution | 80-160 | 160-320 | > 320 |